Black Diamond Therapeutics
Black Diamond Therapeutics designs cancer pills that hit whole families of mutations in a growth protein at once. Its lead drug, silevertinib, targets mutated EGFR in lung cancer and brain tumours.
Overview
Black Diamond Therapeutics is a Cambridge, Massachusetts precision oncology company whose MAP platform designs small molecules that inhibit families of oncogenic mutations. Its lead candidate, silevertinib (formerly BDTX-1535), is a brain-penetrant, mutant-selective EGFR inhibitor: the company lists phase 2 studies in first-line and second/third-line EGFR-mutant non-small cell lung cancer (with FDA Fast Track designation for C797S-positive patients and final phase 2 data at ASCO 2026) and a randomised phase 2 trial in newly diagnosed glioblastoma initiated in the second quarter of 2026. BDTX-4933, a RAF inhibitor for RAF/RAS-mutant solid tumours, has been licensed to Servier, and BDTX-4876 (FGFR2/3) is preclinical. The company completed its Nasdaq IPO in February 2020, raising 231.3 million US dollars gross.
Funding
All startupsInvestors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · 12,174,263 shares including full over-allotment; gross proceeds 231.3 million US dollars, completed February 2020 | 2020 | $231M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Notes
top- Founding year not sourced. The 'braf' target tag reflects the RAF programme BDTX-4933 (RAF/RAS-mutant tumours) rather than a BRAF-specific claim.
Pages like this
not linked directly; found by shared links- ProductDacomitinib
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- PersonThomas J. Lynch Jr.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- InstitutionInstituto Nacional de Oncología y Radiobiología (INOR)
Shares EGFR, Non-small-cell lung cancer.
- ProductIcotinib
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- ProductMobocertinib
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- ProductSunvozertinib
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- CompanyTyra Biosciences
Shares FGFR2, Small-molecule kinase inhibitors.
- CompanyORIC Pharmaceuticals
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer.